- In May 2024, Novartis AG announced expanded global access to Leqvio (inclisiran), its RNA interference-based therapy for lowering LDL cholesterol, by entering into strategic pricing agreements with health ministries across Latin America and Asia. This move aims to improve availability in underserved regions while reinforcing Novartis’ leadership in next-generation lipid management solutions, particularly for patients with statin intolerance or familial hypercholesterolemia
- In March 2024, Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, released new real-world data on Praluent (alirocumab) demonstrating significant reductions in cardiovascular events in high-risk patients when used as an adjunct to statin therapy. The findings, presented at the American College of Cardiology Annual Meeting, highlight the long-term efficacy of PCSK9 inhibitors and support broader clinical adoption
- In February 2024, Ionis Pharmaceuticals, Inc. announced progress in its phase 3 trials for ION449, an investigational antisense therapy targeting PCSK9 mRNA. The therapy is designed to provide durable LDL-C reduction with infrequent dosing. This development underlines the industry's growing focus on RNA-based treatments with improved adherence and efficacy in chronic lipid control
- In January 2024, Esperion Therapeutics, Inc. received FDA approval for expanded indications of Nexletol (bempedoic acid) for primary prevention of cardiovascular disease in patients unable to tolerate statins. The approval marks a significant milestone for patients seeking alternative oral lipid-lowering therapies, reinforcing the company's commitment to addressing unmet needs in cholesterol management
- In December 2023, Amgen Inc. launched a global educational initiative in partnership with major cardiology associations to raise awareness about the importance of LDL-C reduction and early intervention. Focused on Asia-Pacific and Europe, the campaign promotes better screening and access to therapies such as Repatha (evolocumab), particularly among populations with familial hypercholesterolemia and a history of cardiovascular events
